Impedimed Limited IPD
ASX · Australia · Health Technology
AUD 0.004000-0.00 (-20.00%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
ImpediMed, a leader in the development and commercialization of medical technologies to clinically monitor and manage fluid and body composition, today announced it has received U.S. Food and Drug Administration 510(k) clearance for sarcopenia risk assessment on its SOZO® Digital Health Platform. Under the new indication, the SOZO system may be used to assess patients at risk of sarcopenia, a disease of low muscle mass or muscle loss. The clearance makes SOZO the only FDA-cleared bioimpedance sp
ImpediMed, a leader in the development and commercialization of medical technologies to clinically monitor and manage fluid and body composition, and its Board of Directors have announced the appointment of Erik Anderson as Managing Director and Chief Executive Officer. Anderson, who joined the company's Board of Directors in February 2026, succeeds Dr. Parmjot Bains. His appointment is effective April 7, 2026.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.